Clinical Trials Logo
  1. Home
  2. Leukemia, Lymphocytic, Chronic
  3. NCT00289549

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic Clinical Trial

Official title:
Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical Trial Summary

Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00289549
Study type Interventional
Source BioCryst Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date June 2005
Completion date January 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03204188 - Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Completed NCT02758665 - Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT00562224 - Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients Phase 1
Completed NCT00186303 - Transplantation for Patients With Chronic Lymphocytic Leukemia N/A
Completed NCT00270049 - Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia Phase 2
Terminated NCT02440685 - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00083473 - A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia Phase 2
Completed NCT04030195 - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Phase 1/Phase 2
Completed NCT00464633 - Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Phase 2
Terminated NCT00290407 - Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) Phase 2
Completed NCT00055146 - Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Phase 2
Not yet recruiting NCT05154474 - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Terminated NCT01045382 - MSC and HSC Coinfusion in Mismatched Minitransplants Phase 2
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00283101 - A Safety Study in Patients With Chronic Lymphocytic Leukemia Phase 1/Phase 2
Completed NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Phase 1/Phase 2
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2
Completed NCT00535912 - Phase III Study Treatment of CLL B and C Phase 3